绘制具有确定身份的有机可萃取物和可浸出物的图谱。

Q3 Medicine
Dennis Jenke, Piet Christiaens, Adam Jenke, Jan Baeten, Philippe Verlinde, Jean-Marie Beusen
{"title":"绘制具有确定身份的有机可萃取物和可浸出物的图谱。","authors":"Dennis Jenke, Piet Christiaens, Adam Jenke, Jan Baeten, Philippe Verlinde, Jean-Marie Beusen","doi":"10.5731/pdajpst.2025-000007.1","DOIUrl":null,"url":null,"abstract":"<p><p>Drug product leachables are substances that are leached from the drug products manufacturing system components during manufacturing operations, drug product packaging systems during storage over shelf-life, and delivery systems during administration. Medical device leachables are substances that are released from medical devices during their clinical use. Thus, packaged drug products and medical devices are profiled for leachables (and/or extractables as probable leachables) to establish that the levels of leachables are sufficiently small that they present a negligible risk of adversely affecting patient health. This profiling is accomplished by screening the drug product or extracts of the medical device for released organic substances via nontargeted analysis (NTA) employing chromatographic methods coupled with mass spectrometric detection.The topics of how many possible organic extractables and leachables (E&L) there are and what are the most commonly reported organic E&Ls has been widely discussed in the E&L community of practice.One means of charting this universe of organic extractables and leachables is to review and collate those substances that have been encountered over the course of performing E&L studies. To this end, Nelson Labs Europe, a major contract research organization performing E&L testing for decades, has collated the results of several thousand E&L studies performed over the past several years, representing modern best practices in E&L assessment. These collated results, considering only those compounds reported with confirmed identities, are summarized and discussed herein. Although the use of compounds with only confirmed identities limits the number of considered compounds somewhat, so doing ensures that potentially false identifications and not published and do not result in a biased analysis of the collected information.</p>","PeriodicalId":19986,"journal":{"name":"PDA Journal of Pharmaceutical Science and Technology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Charting the Universe of Organic Extractables and Leachables Compounds with Confirmed identities.\",\"authors\":\"Dennis Jenke, Piet Christiaens, Adam Jenke, Jan Baeten, Philippe Verlinde, Jean-Marie Beusen\",\"doi\":\"10.5731/pdajpst.2025-000007.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Drug product leachables are substances that are leached from the drug products manufacturing system components during manufacturing operations, drug product packaging systems during storage over shelf-life, and delivery systems during administration. Medical device leachables are substances that are released from medical devices during their clinical use. Thus, packaged drug products and medical devices are profiled for leachables (and/or extractables as probable leachables) to establish that the levels of leachables are sufficiently small that they present a negligible risk of adversely affecting patient health. This profiling is accomplished by screening the drug product or extracts of the medical device for released organic substances via nontargeted analysis (NTA) employing chromatographic methods coupled with mass spectrometric detection.The topics of how many possible organic extractables and leachables (E&L) there are and what are the most commonly reported organic E&Ls has been widely discussed in the E&L community of practice.One means of charting this universe of organic extractables and leachables is to review and collate those substances that have been encountered over the course of performing E&L studies. To this end, Nelson Labs Europe, a major contract research organization performing E&L testing for decades, has collated the results of several thousand E&L studies performed over the past several years, representing modern best practices in E&L assessment. These collated results, considering only those compounds reported with confirmed identities, are summarized and discussed herein. Although the use of compounds with only confirmed identities limits the number of considered compounds somewhat, so doing ensures that potentially false identifications and not published and do not result in a biased analysis of the collected information.</p>\",\"PeriodicalId\":19986,\"journal\":{\"name\":\"PDA Journal of Pharmaceutical Science and Technology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PDA Journal of Pharmaceutical Science and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5731/pdajpst.2025-000007.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PDA Journal of Pharmaceutical Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5731/pdajpst.2025-000007.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

药品可浸出物是指在生产操作过程中从药品生产系统组件中浸出的物质,在储存期间从药品包装系统中浸出的物质,以及在给药期间从给药系统中浸出的物质。医疗器械浸出物是指医疗器械在临床使用过程中释放出来的物质。因此,对包装药品和医疗器械的可浸出物(和/或可提取物作为可能的可浸出物)进行分析,以确定可浸出物的水平足够小,对患者健康产生不利影响的风险可以忽略不计。通过非靶向分析(NTA),采用色谱方法和质谱检测,筛选医疗器械的药品或提取物中释放的有机物质,从而完成该分析。有多少可能的有机萃取物和浸出物(E&L),以及什么是最常见的有机萃取物和浸出物的主题在有机萃取物和浸出物的实践社区中被广泛讨论。绘制有机可萃取物和可浸出物图谱的一种方法是回顾和整理在进行E&L研究过程中遇到的那些物质。为此,Nelson实验室欧洲,一个主要的合同研究组织,几十年来一直在进行E&L测试,已经整理了过去几年中进行的几千项E&L研究的结果,代表了E&L评估的现代最佳实践。这些整理的结果,只考虑那些化合物报道与确认的身份,总结和讨论在这里。虽然只使用已确认身份的化合物在一定程度上限制了所考虑的化合物的数量,但这样做可以确保潜在的错误鉴定而不被公布,并且不会导致对收集到的信息的有偏见的分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Charting the Universe of Organic Extractables and Leachables Compounds with Confirmed identities.

Drug product leachables are substances that are leached from the drug products manufacturing system components during manufacturing operations, drug product packaging systems during storage over shelf-life, and delivery systems during administration. Medical device leachables are substances that are released from medical devices during their clinical use. Thus, packaged drug products and medical devices are profiled for leachables (and/or extractables as probable leachables) to establish that the levels of leachables are sufficiently small that they present a negligible risk of adversely affecting patient health. This profiling is accomplished by screening the drug product or extracts of the medical device for released organic substances via nontargeted analysis (NTA) employing chromatographic methods coupled with mass spectrometric detection.The topics of how many possible organic extractables and leachables (E&L) there are and what are the most commonly reported organic E&Ls has been widely discussed in the E&L community of practice.One means of charting this universe of organic extractables and leachables is to review and collate those substances that have been encountered over the course of performing E&L studies. To this end, Nelson Labs Europe, a major contract research organization performing E&L testing for decades, has collated the results of several thousand E&L studies performed over the past several years, representing modern best practices in E&L assessment. These collated results, considering only those compounds reported with confirmed identities, are summarized and discussed herein. Although the use of compounds with only confirmed identities limits the number of considered compounds somewhat, so doing ensures that potentially false identifications and not published and do not result in a biased analysis of the collected information.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
34
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信